Apimostinel is primarily researched for its potential in treating central nervous system disorders, particularly as an adjunct in anesthesia to enhance recovery and reduce side effects. It is being studied for its ability to modulate NMDA receptors, which play a crucial role in cognitive functions and pain perception. This makes it a candidate for improving outcomes in surgeries and managing conditions like depression or neuropathic pain. Its application in clinical settings could lead to faster patient recovery and better management of anesthesia-related complications.